MIRA
INFORM REPORT
|
Report Date : |
07.07.2012 |
IDENTIFICATION DETAILS
|
Name : |
APOTEX INC |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Year of Establishment : |
1974 |
|
|
|
|
Com. Reg. No.: |
Not Available |
|
|
|
|
Legal Form : |
Private Branch Company |
|
|
|
|
Line of Business : |
manufacturing,
fabricating, or processing drugs in pharmaceutical preparations for human or
veterinary use |
|
|
|
|
No. of Employees : |
10 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Canada |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
Apotex Inc
50 Steinway Blvd
Etobicoke, ON M9W 6Y3
Canada
Tel: 416-675-0338
Web: www.apotex.com
Registration data
Year Established: 1974
Employees: 10
Company Type: Private Branch
Corporate Family: 24
Companies
Ultimate Parent: Apotex
Holdings Inc
Financials in: USD
(Millions)
Reporting Currency: Canadian
Dollar
Annual Sales: 12.7
Total Assets: NA
Business Description
Establishments primarily engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The greater part of the products of these establishments are finished in the form intended for final consumption, such as ampoules, tablets, capsules, vials, ointments, medicinal powders, solutions, and suspensions. Products of this industry consist of two important lines, namely: (1) pharmaceutical preparations promoted primarily to the dental, medical, or veterinary professions, and (2) pharmaceutical preparations promoted primarily to the public.
Industry
Industry Biotechnology and Drugs
ANZSIC 2006: 1841 - Human
Pharmaceutical and Medicinal Product Manufacturing
NACE 2002: 2442 - Manufacture
of pharmaceutical preparations
NAICS 2002: 325412 -
Pharmaceutical Preparation Manufacturing
UK SIC 2003: 24421 -
Manufacture of medicaments
US SIC 1987: 2834 -
Pharmaceutical Preparations
Key Executives
Name Title
Jack Kay President
News
|
Title |
Date |
|
US Patent Issued to Apotex Technologies on
June 26 for "Crystalline Forms of the Mono-Sodium Salt of
D-Isoglutamyl-D-Tryptophan" (Canadian Inventors) |
30-Jun-2012 |
|
Sanofi Statement on Federal Court of
Canada's ruling on ramipril |
29-Jun-2012 |
|
Merck Leave to Appeal To SCC Dismissed
(Intellectual Property Weekly Abstracts Bulletin, Week Of June 18, 2012) |
27-Jun-2012 |
|
The Impacts Of The Amazon.Com Decisions On
Medical Use Claims In Canada |
27-Jun-2012 |
|
Merck receives
unfavorable judgment in patent suit against Apotex |
25-Jun-2012 |
1 - Profit & Loss Item Exchange Rate: USD 1 = CAD 0.9879405
2 - Balance Sheet Item Exchange Rate: USD 1 = CAD 1.01735
Corporate Overview
Location
50 Steinway Blvd
Etobicoke, ON, M9W 6Y3
Canada
Tel: 416-675-0338
Web: www.apotex.com
Sales CAD(mil): 12.5
Assets CAD(mil): NA
Employees: 10
Industry: Biotechnology
and Drugs
Company Type: Private
Branch
Quoted Status: Not
Quoted
President: Jack
Kay
Year Established: 1974
Contents
Industry Codes
Business Description
Financial Data
Additional Information
Industry Codes
ANZSIC 2006 Codes:
3720 - Pharmaceutical and Toiletry Goods Wholesaling
1841 - Human Pharmaceutical and Medicinal Product Manufacturing
NACE 2002 Codes:
5146 - Wholesale of pharmaceutical goods
2442 - Manufacture of pharmaceutical preparations
NAICS 2002 Codes:
325412 - Pharmaceutical Preparation Manufacturing
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
US SIC 1987:
5122 - Drugs, Drug Proprietaries, and Druggists' Sundries
2834 - Pharmaceutical Preparations
UK SIC 2003:
24421 - Manufacture of medicaments
5146 - Wholesale of pharmaceutical goods
Business
Description
Establishments primarily engaged in manufacturing, fabricating, or processing drugs in pharmaceutical preparations for human or veterinary use. The greater part of the products of these establishments are finished in the form intended for final consumption, such as ampoules, tablets, capsules, vials, ointments, medicinal powders, solutions, and suspensions. Products of this industry consist of two important lines, namely: (1) pharmaceutical preparations promoted primarily to the dental, medical, or veterinary professions, and (2) pharmaceutical preparations promoted primarily to the public.
|
|||||||||||||||||||||||||||||||
|
|
Credit Report as of 12/01/2011
|
Location |
|
|
50 Steinway Blvd |
|
|
|
|
|
County: |
Toronto Metropolitan |
|
|
|
|
Phone: |
416-675-0338 |
|
|
|
|
ABI©: |
027260892 |
|
|
|
|
Annual Sales: |
$12,526,000 (CAD) |
|
Employees: |
10 |
|
|
|
|
Business Type: |
Private |
|
Location Type: |
Branch |
|
Corp. Affiliation: |
|
|
Primary Line of
Business: |
|
|
SIC: |
2834-04 - Drug Millers (Mfrs) |
|
NAICS: |
325412 - Pharmaceutical Preparation Mfg |
|
Secondary Lines
of Business: |
|
|
NAICS: |
424210 - Druggists' Goods Merchant Whols |
|
SICs: |
5122-03 - Pharmaceutical Products-Wholesale |
|
|
||
|
Unilab Surgibone Inc |
Intellipharmaceutics Intl Inc |
Apotex Holdings Inc |
|
Canada Supply Inc |
Pharmax Limited |
Seaford Pharmaceuticals |
|
Apotex Inc |
Taro Pharmaceuticals Inc |
Alcan Packaging |
|
SSL Canada |
|
|
|
Corporate
Family |
Corporate
Structure News: |
|
|
|
|
Apotex Inc |
|
|
|
|
|
Company
Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
Parent |
North York, ON |
Canada |
Biotechnology and Drugs |
|
5,800 |
|
|
Subsidiary |
Toronto, ON |
Canada |
Biotechnology and Drugs |
829.8 |
6,800 |
|
|
Branch |
Richmond Hill, ON |
Canada |
Biotechnology and Drugs |
758.4 |
600 |
|
|
Subsidiary |
Del. Benito JuĂ¡rez, Federal District |
Mexico |
Miscellaneous Capital Goods |
90.0 |
600 |
|
|
Branch |
Brantford, ON |
Canada |
Biotechnology and Drugs |
410.8 |
400 |
|
|
Branch |
Winnipeg, MB |
Canada |
Biotechnology and Drugs |
126.8 |
150 |
|
|
Branch |
Etobicoke, ON |
Canada |
Biotechnology and Drugs |
12.7 |
10 |
|
|
Subsidiary |
North York, ON |
Canada |
Biotechnology and Drugs |
12.7 |
10 |
|
|
Branch |
Pointe-Claire, QC |
Canada |
Personal and Household Products |
11.1 |
6 |
|
|
Branch |
Calgary, AB |
Canada |
Personal and Household Products |
11.1 |
6 |
|
|
Branch |
North York, ON |
Canada |
Personal and Household Products |
10.3 |
6 |
|
|
Branch |
Ottawa, ON |
Canada |
Biotechnology and Drugs |
|
4 |
|
|
Branch |
Ottawa, ON |
Canada |
Biotechnology and Drugs |
|
4 |
|
|
Subsidiary |
Istanbul, Istanbul |
Turkey |
Miscellaneous Capital Goods |
|
|
|
|
Subsidiary |
North Ryde, NSW |
Australia |
Personal and Household Products |
|
|
|
|
Subsidiary |
Chaoyang District, Beijing |
China |
Miscellaneous Capital Goods |
|
|
|
|
Subsidiary |
Winnipeg, MB |
Canada |
Biotechnology and Drugs |
149.7 |
700 |
|
|
Subsidiary |
Toronto, ON |
Canada |
Personal and Household Products |
149.7 |
700 |
|
|
Subsidiary |
Baltimore, MD |
United States |
Biotechnology and Drugs |
32.2 |
125 |
|
|
Subsidiary |
Altamonte Springs, FL |
United States |
Business Services |
3.2 |
16 |
|
|
Branch |
Winnipeg, MB |
Canada |
Personal and Household Products |
11.1 |
6 |
|
|
Subsidiary |
Winnipeg, MB |
Canada |
Healthcare Facilities |
|
6 |
|
|
Subsidiary |
Van Nuys, CA |
United States |
Business Services |
|
|
|
|
Subsidiary |
Bruxelles |
Belgium |
Personal and Household Products |
2.8 |
11 |
Executive report
|
Executives |
|
|
|
|
||||
|
President |
President |
|
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.42 |
|
UK Pound |
1 |
Rs.86.04 |
|
Euro |
1 |
Rs.68.61 |
INFORMATION DETAILS
|
Report Prepared by
: |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.